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1726-4ReplyWe appreciate Dr. Wang’s1 comments on our recently
published article in JCMA.2 Dr. Wang has exhibited great
concern about the cost-effectiveness of mammographic
screening, given that the incidence rate (IR) and mortality rate
of breast cancer both increased after initiation of this screening
program. It has been shown that this screening program is
considerably inferior to the clinical outcome of Pap smear
screening in cervical cancer. After decades of development,
Pap smear for use in cervical cancer screening has achieved a
significant clinical outcome - the IR of invasive cervical
cancer is lower than that of precancer lesions.1 The risk factors
of breast cancer are multifactorial, including race, age, gene,
hormone, diet and so on. Therefore, it is impractical to expect
to reduce the IR of breast cancer from mammographic
screening, or further enhance cervical cancer screening by Pap
smear. A screening program is used to detect lesions at an
earlier stage, and hopefully reduce subsequent medical
expense and mortality. The increased IR and mortality rate of
breast cancer in recent years underscores the importance of
this medical issue. The 33% two-year coverage rate of the
nationwide mammographic screening is still less than optimal
as compared with that of Pap smear (57%) in cervical cancer.
But the increased cancer detection rate (from 3.94 to 5.04‰)
with elevated early cancer detection (from 15.7% in 2004 to
around 40% in recent years) also indicates that the interpreting
skills of screening radiologists have improved, as well as the
overall mammographic screening outcome.
We agree with Dr. Wang’s opinion that the subsequent
medical charge and emotional challenge after an unnecessary
recall remain a notable concern. In a screening program, even
the cytological diagnosis of Pap smear may have false positive-
or negative results, not to mention the diagnostic vagaries pre-
sented in mammographic screening. To achieve a reasonable
recall rate percentage for both false positives and negatives
alike, we have conducted a mammographic screening peer
reviewing and medical auditing system in Taiwan.3 Currently,
the above-mentioned data are all nearly within the American
College ofRadiology (ACR) recommended level. Regarding the
next step in abnormal mammography screening, there is already
a well-established BI-RADS system4 to follow. Mammograms
assessed as BI-RADS 1,2 or 3 (recommends short-term follow-
up) are defined as negative, while those assessed as BI-RADS 0x.doi.org/10.1016/j.jcma.2014.12.004
901/Copyright © 2014 Elsevier Taiwan LLC and the Chinese Medical Ass(needs additional examination), 4 or 5 are defined as positive.
Additional imaging modalities such as 3-D tomosynthesis,5
contrast tomosynthesis6 or breast MRI7 may also be used to
alleviate the incidence of unnecessary recall or biopsy. How-
ever, further analysis of the financial cost and emotional support
is beyond the scope of this article.
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